By vgreene, 18 February, 2020 If SGLT2-I not tolerated or contraindicated or if eGFR less than adequate, add GLP-1 RA w/ proven CVD benefit1 [A]
By vgreene, 18 February, 2020 Efficacy, hypoglycemia risk,<sup>3</sup> and wt concerns to consider when selecting antihyperglycemic tx:
By vgreene, 18 February, 2020 Efficacy, hypoglycemia risk,<sup>1</sup> and wt concerns to consider when selecting antihyperglycemic tx:
By vgreene, 18 February, 2020 Efficacy, hypoglycemia risk,<sup>3</sup> and wt concerns to consider when selecting antihyperglycemic tx: